Martin Kampmann, Ph.D., explores how CRISPR screening and induced pluripotent stem cell (iPSC) technology can uncover new insights into neurological diseases such as Alzheimer's. His lab uses CRISPR to identify genes that influence protein aggregation and cellular vulnerability, focusing on neurons, astrocytes, and microglia derived from human stem cells. Kampmann highlights the roles of mitochondria, autophagy, and other cellular pathways in disease progression, emphasizing the importance of understanding both protective and damaging processes. He also discusses the potential contributions of glial cells—especially microglia and astrocytes—to neurodegeneration, sparking ideas for therapeutic targets. (#39461)